Other approaches include utilizing IL-18 secreting CAR T cells and IL-18-based adoptive transfer (such as IL-12/IL-15/IL18 preactivated NK cells) (90, 91) with ongoing clinical trials as promising results were seen in early clinical trials of AML patients (92, 93). Here, IL18 is linked to acute myeloid leukemia.